Quote | NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)
Last: | $0.809363 |
---|---|
Change Percent: | 0.86% |
Open: | $0.803 |
Close: | $0.809363 |
High: | $0.845 |
Low: | $0.7801 |
Volume: | 44,286 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
Message Board Posts | NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)
Subject | By | Source | When |
---|---|---|---|
If the relationship goes well they might do | McMagyar | investorshub | 06/22/2023 12:14:56 PM |
Just saw its an engagement with bioscam.. Who would | McMagyar | investorshub | 06/22/2023 12:12:56 PM |
$NRSN MomentumIts trading last trade up | THEMASTERS_SON | investorshub | 06/15/2023 7:04:58 PM |
oh yeah news for the day | THEMASTERS_SON | investorshub | 06/15/2023 11:36:18 AM |
$NRSN The gaining | frankyahoo | investorshub | 06/15/2023 6:18:46 AM |
News, Short Squeeze, Breakout and More Instantly...
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...